Im­muneer­ing touts pos­i­tive pan­cre­at­ic can­cer da­ta for MEK in­hibitor

Im­muneer­ing’s shares rock­et­ed in pre­mar­ket trad­ing on Tues­day on the back of pos­i­tive mid-stage da­ta for its MEK in­hibitor in pan­cre­at­ic can­cer, spark­ing plans to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER